Tech Center 1600 • Art Units: 1623
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17639318 | Use of Deoxycholic Acid, Derivatives, or Salts Thereof in Managing Bacterial Infections and Compositions Related Thereto | Non-Final OA | Emory University |
| 19293697 | Cisplatin particles and uses thereof | Non-Final OA | CRITITECH, INC. |
| 17841729 | NO-RINSE FRESHENING COMPOSITIONS FOR TREATING INANIMATE SURFACES | Non-Final OA | The Procter & Gamble Company |
| 17629252 | MULTIVALENT FIBROBLAST-TARGETED AGENTS AND METHODS OF USE | Non-Final OA | Purdue Research Foundation |
| 18550237 | KRAS INHIBITORS | Non-Final OA | Bristol-Myers Squibb Company |
| 17802896 | MAP KINASE KINASE (MKK7) INHIBITORS AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17773992 | SELECTIVE DUAL HISTONE DEACETYLASE 6/8 (HDAC6/8) DEGRADERS AND METHODS OF USE THEREOF | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17772384 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17998275 | ATR INHIBITORS FOR THE TREATMENT OF CANCER | Non-Final OA | AstraZeneca AB |
| 17771896 | COMPOUNDS AND METHODS FOR POTENTIATING COLISTIN ACTIVITY | Final Rejection | University of Notre Dame du Lac |
| 18032096 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | Non-Final OA | Bayer Aktiengesellschaft |
| 18032067 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | Non-Final OA | Bayer Aktiengesellschaft |
| 18004965 | Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride | Non-Final OA | Pfizer Inc. |
| 18043441 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | Non-Final OA | Albert Einstein College of Medicine |
| 17790172 | 11-(4-CHLOROPHENYL)-4-(2,3-DIHYDRO-1H-INDOLE-1-CARBONYL)-3,11-DIMETHYL-5,10,DIOXATRICYCLO[7.4.0.0,2,6,]TRIDECA-1,3,6,8-TETRAEN-13-ONE AND DERIVATIVES AS DESTABILIZER OF CRY1 FOR THE TREATMENT OF CIRCADIAN RHYTHM ASSOCIATED DISEASES AND DISORDERS | Final Rejection | KOC UNIVERSITESI |
| 18031714 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | Non-Final OA | Blueprint Medicines Corporation |
| 18385277 | GLUTARIMIDES FOR MEDICAL TREATMENT | Final Rejection | C4 Therapeutics, Inc. |
| 17723199 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | Non-Final OA | C4 Therapeutics, Inc. |
| 18562251 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME AND THERAPEUTIC USE THEREOF | Non-Final OA | École Nationale Supérieure de Chimie de Montpellier |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | Non-Final OA | MUSC Foundation for Research Development |
| 17885578 | ERBB RECEPTOR INHIBITORS | Final Rejection | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| 17633980 | ENZYME INHIBITORS | Non-Final OA | KALVISTA PHARMACEUTICALS LIMITED |
| 17712780 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | Non-Final OA | Tenaya Therapeutics, Inc. |
| 17641162 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Final Rejection | SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD. |
| 18252717 | CAPSAICYNS IN THE TREATMENT OF LEAKY GUT | Non-Final OA | AXICHEM AB [SE]/[SE] |
| 18249195 | PHARMACEUTICAL COMPOSITION BASED ON NALBUPHINE AND/OR ITS SALTS FOR NASAL ADMINISTRATION | Non-Final OA | Pharmbiotest Poland Sp. z o. o. |
| 18032098 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | Non-Final OA | CarthroniX, Inc. |
| 18157224 | MTORC1 MODULATORS AND USES THEREOF | Non-Final OA | Aeovian Pharmaceuticals, Inc. |
| 17921509 | METHODS OF TREATING ABNORMAL CELL GROWTH | Non-Final OA | Verastem, Inc. |
| 17915275 | PHARMACEUTICAL COMBINATION AND USE THEREOF | Final Rejection | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy